Search results for "Cholestyramine"

showing 3 items of 3 documents

Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine

1977

The effect of cholestyramine (12 gm/day divided into 3 doses) on the pharmacokinetics and pharmacodynamics of a single intravenouse dose (30 mg) of phenprocoumon was studied in 6 normal subjects. Cholestyramine treatment led to an increase in the rate of elimination of phenprocoumon in all. Total clearance increased 1.5- to 2-fold. The total anticoagulant effect per dose was considerably reduced during treatment with cholestyramine. Binding studies in vitro showed that phenprocoumon is strongly bound to cholestyramine and that at a given cholestyramine concentration the percentage of phenprocoumon bound remained constant over a large concentration range of phenprocoumon. The results suggest…

AdultMalePharmacologyCholestyramineAnticoagulant effectDose-Response Relationship DrugChemistryCholestyramine Resin4-HydroxycoumarinsMiddle AgedPharmacologyPhenprocoumonLiverPharmacokineticsEnterohepatic CirculationPhenprocoumonmedicineHumansPharmacology (medical)Enterohepatic circulationHalf-Lifemedicine.drugClinical Pharmacology & Therapeutics
researchProduct

Combined pharmacological treatment of heterozygous familial hypercholesterolemia

1990

Combined therapy of heterozygous familial hypercholesterolemia using a non-systemically acting drug (bile acid sequestrants) and a systemically acting one is frequently employed in clinical practice. A brief review of this topic is presented, with particular emphasis on the use of cholestyramine combined with pravastatin, a new HMG CoA reductase inhibitor.

DrugCholestyramineBile acidbiologymedicine.drug_classbusiness.industrymedia_common.quotation_subjectnutritional and metabolic diseasesFamilial hypercholesterolemiaMevalonic acidPharmacologymedicine.diseasePharmacological treatmentchemistry.chemical_compoundchemistryHMG-CoA reductasemedicinebiology.proteinbusinessPravastatinmedicine.drugmedia_common
researchProduct

Adsorption of methotrexate and calcium leucovorin onto cholestyramine in vitro.

2003

Abstract Methotrexate (MTX), an antimetabolite of folic acid, is a drug widely used in the treatment of different types of cancer. When high doses are administered, it is necessary to interrupt its action by administering calcium leucovorin (CaL). The main pathway of MTX and CaL elimination in humans occurs through the kidney, but about 10% is excreted in the faeces via the bile. Drugs, foods and sorbents in intestinal lumen modify MTX and CaL reabsorption. Individual and simultaneous studies on the adsorption of MTX and CaL from aqueous phosphate buffer by cholestyramine were carried out in order to calculate the adsorption process of MTX and CaL to cholestyramine, and to characterize the …

musculoskeletal diseasesDrugAntimetabolites Antineoplasticmedicine.drug_classmedia_common.quotation_subjectCholestyramine ResinLeucovorinPharmaceutical SciencePharmacologyAntimetabolitechemistry.chemical_compoundmedicineIon-exchange resinAnion Exchange Resinsmedia_commonLeucovorin CalciumKidneyCholestyramineChromatographyChemistryHydrogen-Ion Concentrationstomatognathic diseasesmedicine.anatomical_structureMethotrexateAntifolateMethotrexateAdsorptionmedicine.drugInternational journal of pharmaceutics
researchProduct